康方生物(09926.HK) 公布，公司自主研发的全球首创PD-1/VEGF双特异性肿瘤免疫治疗药物依沃西单抗注射液，其国际市场开发合作伙伴Summit Therapeutics(SMMT.US) 已与美国辉瑞(PFE.US) 达成临床试验合作，将共同推进依沃西与辉瑞多款抗体偶联(ADCs)药物在多种实体瘤中的联合治疗应用。
根据协议条款，辉瑞将全面负责本次合作的系列临床试验的开展，Summit将提供依沃西用于该系列临床试验，双方共同监督临床研究的进行，并各自保留其产品的相关权利。目前依沃西在全球开展临床试验药物均由康方生物生产供应。
公司预期，本次与多种创新性ADCs药物的联合应用，将有助于更快速、更深入和充分地挖掘依沃西作为新一代肿瘤免疫治疗双抗新药在全球市场的临床价值和商业价值，建立依沃西在肿瘤治疗领域持续的迭代优势。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-24 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.